Genta Inc. (GETA.OB) Forms Strategic Alliance with MedCI to License Cancer Drug
Genta Inc., the biopharma company with a wide-ranging portfolio focused primarily on DNA/RNA and Small Molecule medicines, announced a strategic alliance with MedCI LLC, the well-known life-science consulting services company, with the goal of finding licensing partners for Genta’s small molecule oncology compound tesetaxel. Part of Genta’s overall oncology approach, tesetaxel is the No. 1 taxane for oral delivery currently under clinical development. The compound has shown good results in several Phase 2 trials, eliminating the infusion reactions associated with other competing taxanes and reducing the nerve damage seen with other taxanes to negligible status. Genta’s Business Development initiatives to…